2019
Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking
Bold KW, Zweben A, Fucito LM, Piepmeier ME, Muvvala S, Wu R, Gueorguieva R, O'Malley SS. Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking. Alcohol Clinical And Experimental Research 2019, 43: 937-944. PMID: 30817018, PMCID: PMC7039307, DOI: 10.1111/acer.13994.Peer-Reviewed Original ResearchConceptsEnd of treatmentAlcohol use disorderHeavy drinking daysMedical managementCigarette smokingComorbid cigarette smokingUse disordersDrinking daysCo-occurring alcohol use disorderHigh ratePlacebo-controlled trialBetter clinical outcomesAssessment of alcoholPercent of participantsVarenicline treatmentClinical outcomesSmoking abstinenceParallel groupClinical trialsTimeline FollowVareniclineSmoking behaviorAlcohol treatmentPosttreatment outcomesMultisite trial
2016
Longitudinal Findings From a Randomized Clinical Trial of Naltrexone for Young Adult Heavy Drinkers
DeMartini KS, Gueorguieva R, Leeman RF, Corbin WR, Fucito LM, Kranzler HR, O’Malley S. Longitudinal Findings From a Randomized Clinical Trial of Naltrexone for Young Adult Heavy Drinkers. Journal Of Consulting And Clinical Psychology 2016, 84: 185-190. PMID: 26654213, PMCID: PMC4941818, DOI: 10.1037/ccp0000053.Peer-Reviewed Original ResearchConceptsPercent days abstinentFirst placebo-controlled trialPercent days heavy drinkingHeavy drinkingPlacebo-controlled trialLong-term outcomesHeavy drinking daysYoung adults ages 18Adults ages 18Naltrexone conditionActive medicationPlacebo groupPharmacotherapy trialsAdult heavy drinkersYoung adult heavy drinkersNonsignificant decreaseSignificant benefitsYear posttreatmentDays abstinentDrinking daysMost outcomesSingle interventionHeavy drinkersTreatment improvementAge 18